 |
» |
|
|
 |
Pursuing Technology to Drive the Development of the Next Generation of Diagnostics and Pharmaceuticals—Some Challenges Facing the Pharmaceutical Industry |
 |
 |
David K. Rosen, D.V.M., Head, Development and Commercial Alliances, Pfizer Global Research & Development
Life sciences research has traditionally followed an ordered and isolated process in the move towards advancing new treatments or therapies into clinical development (and eventually towards a commercial therapeutic product). However, given the ever growing quantities and availability of new relevant data as well as ongoing data integration initiatives within organizations, researchers must now be mindful of how their efforts could be affected by human biology, including patient-specific knowledge that can lead to personalized medicine solutions. Specifically, in those cases where human variation directly impacts drug efficacy or adverse events, early data and insights from potential biomarker variations in humans, in silico disease modeling, and new technology process innovations can strongly impact success of researcher efforts, despite their origins from other parts of the life sciences value chain. This presentation will discuss the impact of personalized medicine on the conduct of life sciences research and its increasing influence on changing current research practices.
|

|
 |
|
|